BIOCYTOGEN
3.1.2023 15:24:36 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MUFG Investor Services Appoints McAllister Kirschner Chief Executive Officer27.10.2026 14:15:00 CET | Press release
MUFG Investor Services today announced the appointment of McAllister (Mac) Kirschner as Chief Executive Officer, effective immediately. John Sergides has stepped down as Chief Executive Officer of MUFG Investor Services for health-related reasons. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027545977/en/ McAllister (Mac) Kirschner Appointed Chief Executive Officer of MUFG Investor Services Kirschner has served as Chief Operating Officer of MUFG Investor Services since 2018, overseeing business and banking operations across public and private markets. He joined MUFG Investor Services in 2016 and previously served as Global Head of Relationship Management, bringing extensive knowledge of the business, its clients, and operations. Before joining MUFG Investor Services, Kirschner was a Managing Director in BlackRock’s Global Fund Services business, where he led teams responsible for shareholder servicing, fund administrati
FEINDEF 27 Has Already Booked 94% of Its Exhibition Space Seven Months Ahead of the Event27.10.2026 14:03:00 CET | Press release
The International Defence and Security Exhibition of Spain (FEINDEF 27) has booked 94% of its exhibition space for 18 to 20 May 2027 at IFEMA Madrid, reflecting strong demand and interest among companies and institutions across the sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027170443/en/ Ángel Olivares, President of the Feindef Foundation Fundación Feindef announced the figure on Monday at the official presentation of the exhibition's fifth edition, held at Madrid's Rafael del Pino Auditorium. The fair is expected to cover more than 89,000 square metres, 46% more than in 2025. More than 746 exhibitors have been confirmed, up 19% on the previous edition. Of these, 37% are first-time participants and over 250 are international exhibitors, accounting for 33% of the total. The event will feature 14 international pavilions, strengthening its international reach as the defence and security industry gains prominence
Taktile Launches AI-Powered Insights to Accelerate How Banks and Insurers Learn From Decisions27.10.2026 14:00:00 CET | Press release
New solution empowers teams to "talk to their data" in natural language and get instant insights to optimize toward KPIs faster Taktile, the leader in AI transformation for financial institutions, today announced the launch of Taktile Insights. The new AI-powered solution enables banks and insurers to analyze decision performance faster than ever before, and quickly identify opportunities for improvement through natural-language prompts. While many banks and insurers have automated large parts of decision processes like loan approvals or claims assessments, evaluating performance can still take days or weeks. In a world where AI automates more than ever, the new differentiator won’t be who makes decisions fastest, but who learns and iterates fastest. Taktile Insights allows the people responsible for these processes to ask their decision data a question, instantly generate charts, and act on insights, without relying on separate data teams. “Banks and insurers have spent years investin
Cognite Spotlights UAE Industrial AI Momentum and Honors Regional Leaders at Impact World Tour Event in Abu Dhabi27.10.2026 14:00:00 CET | Press release
Regional leaders Borouge International, ADNOC Gas, ADNOC Offshore, and ADNOC Upstream take center stage to showcase enterprise-scale achievements in Industrial AI Cognite, the recognized global leader in Industrial AI, today announced the regional winners of its AI Impact Awards. Representatives from honorees ADNOC Gas and ADNOC Upstream joined nearly 200 senior leaders from energy, gas, and petrochemical organizations across the region at the latest stop on Cognite’s 2026 Impact World Tour, which has already visited Houston, Oslo, Mumbai, and Tokyo, with more events scheduled through the end of the year. Celebrating Regional Leadership: The AI Impact Awards The AI Impact Awards Program celebrates achievements in AI-driven innovation, operational excellence, and the use of the Cognite Industrial AI and Data Platform to transform asset-heavy operations to be safer, more sustainable, and profitable. Cognite honors regional winners at World Tour events as part of the agenda’s focus on rea
NTT DATA Expands AI Factory Footprint Globally to Help Clients Scale AI from Pilots to Production27.10.2026 14:00:00 CET | Press release
NTT DATA AI Factories help clients validate priority AI use cases, infrastructure, security, governance and economics before scaling into production. The environments bring together NTT DATA’s full-stack AI expertise with technologies from leading ecosystem partners, including Cisco and NVIDIA. NTT DATA AI Factories open in North America, Europe, Asia-Pacific and the Middle East. NTT DATA, a global leader in AI, digital business and technology services, today announced the global expansion of NTT DATA AI Factories, which provide hands-on environments where organizations can determine how priority AI use cases can be deployed, secured, governed and operated at scale. The environments help business and technology leaders evaluate AI workloads against real-world requirements including infrastructure architecture, performance, workload placement and cost. NTT DATA’s market research shows enterprise leaders want greater confidence about performance and business value before scaling AI inves
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom